TryHard Holdings Limited Announces Closing of Initial Public Offering - Tryhard Holdings (NASDAQ:THH)

Zealand Pharma reported that Boehringer Ingelheim's survodutide achieved co-primary endpoints in its Phase III trial, with participants experiencing up to 13.1% weight loss compared to 3.1% for placebo over 76 weeks. The drug also improved glycemic control in adults with obesity or type 2 diabetes, according to the company.

Sanofi (SASY) shares rose 1.4% to €73.65 after announcing an $8B collaboration with Regeneron to co-develop and co-commercialize four new antibodies. The deal includes a $1B upfront payment and up to $7B in milestone payments. Analysts have a Buy rating and a 12-month price target of €94.06, suggesting significant upside from current levels.

Stifel upgraded Hub Group (HUBG) to Hold from Sell with a $29.00 price target. The stock trades near its 52-week low at $29.58, down 29.86% YTD. Stifel cites improved risk/reward balance due to the price decline, despite accounting issues and earnings uncertainty. UBS maintains a Neutral rating with a $38.00 target. Hub Group faces accounting challenges and a leadership change.

FrontView REIT, Inc.'s average stock price target was reduced from $22.42 to $22.29 by 12 analysts, with a range of $19 to $24. This implies a 34% upside from the Sep. 30 closing price. The consensus rating remains 'Buy' with 9 Buys, 2 Holds, and 1 Sell.

Infineon Technologies (IFNNY) opened a $1.4B manufacturing plant in Thailand, expanding its presence in Southeast Asia. The facility, near Bangkok, will support the region's semiconductor industry growth. According to the company, this move aligns with Thailand's long-term strategy. The investment underscores Infineon's commitment to the area. Investors may watch for potential supply chain and market impact. (350 characters)

Wedbush reiterated an Outperform rating and $47 price target for Jade Biosciences (JBIO) after positive preclinical data for JADE301. The stock is up 54% over the past year. Analysts expect key data readouts in 2027. Jade Biosciences has no debt and a strong cash position. Multiple analysts have raised price targets and maintained positive ratings.